Related Experiment Video
Updated: Sep 24, 2025
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Catheter directed thrombolysis for deep vein thrombosis in 2022: Rationale, evidence base and future directions
Muhammad Umar Khalid1, Maninder Singh2, Vladimir Lakhter2
1Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, USA.
Insights
Catheter directed thrombolysis (CDT) offers benefits for deep vein thrombosis (DVT) patients by improving symptoms and reducing recurrence. Careful patient selection and technique refinement are key to maximizing CDT
Area of Science:
- Vascular Medicine
- Interventional Cardiology
- Thrombosis Management
Background:
- Deep vein thrombosis (DVT) significantly impacts quality of life and healthcare costs.
- Catheter directed thrombolysis (CDT) and pharmaco-mechanical catheter directed thrombolysis (PCDT) aim to accelerate symptom resolution and decrease recurrence in DVT patients.
Purpose of the Study:
- To review factors influencing outcomes in catheter directed thrombolysis for proximal deep vein thrombosis.
- To identify patient subsets and procedural improvements that enhance CDT efficacy.
Main Methods:
- Review of existing literature and four randomized controlled trials (RCTs) on CDT and PCDT for acute proximal DVT.
- Analysis of factors such as bleeding risk, procedural technique, equipment, and endpoints.
Main Results:
- CDT may decrease post-thrombotic syndrome (PTS) severity in selected proximal DVT patients with low bleeding risk.
- Existing RCTs show potential clinical benefits of CDT/PCDT over anticoagulation alone but have limitations in methodology.
Conclusions:
- Optimizing CDT outcomes requires careful patient selection, focusing on those with proximal DVT and low bleeding risk.
- Improvements in procedural techniques, equipment standardization, and objective endpoints are necessary to further establish CDT/PCDT benefits.
Introduction:
Catheter directed thrombolysis (CDT) has evolved as a treatment modality for patients diagnosed with proximal and caval deep vein thrombosis (DVT) and has shown to be superior in certain subset of patient population despite conflicting evidence as seen in the large 4 randomized controlled trials.
Rationale For Cdt In Acute Dvt Patients:
DVT adversely affects the quality of life and adds significantly to the treatment and hospitalization costs. CDT and pharmaco-mechanical catheter directed thrombolysis (PCDT) has been shown to accelerate symptom resolution, decrease symptom severity and decrease recurrence rates with successful procedures in certain patients.
Randomized Clinical Trials (Rcts):
Four RCTs have evaluated the use of CDT and PCDT in acute proximal DVT patients suggesting clinical benefit compared to anticoagulation alone. These trials suggested using CDT for proximal DVT patients with a lower bleeding risk as CDT may decrease PTS. Successful CDT treatment showed improvement in moderate to severe symptoms of post thrombotic syndrome (PTS). However, these studies have limitations including the use of non-standard techniques, different equipment and different endpoints.
Future Directions And Conclusion:
Our goal is to highlight the factors which can potentially improve CDT outcomes in proximal DVT patients. Based on studies, patients with proximal DVT and a low bleeding risk may benefit from early CDT by decreased symptom severity of PTS, however, improvement in procedural technique, equipment and procedural success rates is necessary. With appropriate patient selection, and objective endpoints, we can further establish the benefit of CDT and PCDT in acute DVT patients.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:30Venous Thrombosis I: Introduction
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:30Venous Thrombosis IV: Nursing Management
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...